/CNW/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing...
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial plan...
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll clinical...
FN Media Group Presents Microsmallcap.com Market Commentary  New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,...
/PRNewswire/ -- A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer's disease, announcing recently that it has gotten...
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian company that makes natural, scalable, and easy-to-get psychedelic and functional mushrooms, as well as synthetic formulations, to help people...
FN Media Group Presents Microsmallcap.com Market Commentary  New York, NY – September 7, 2022 – According to a new survey by Johns Hopkins Medicine researchers, people’s attitudes toward death...
/PRNewswire/ -- According to a new survey by Johns Hopkins Medicine researchers, people's attitudes toward death change after a psychedelic drug experience and...
FN Media Group Presents Microsmallcap.com Market Commentary  New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health...
/PRNewswire/ -- Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to...